Advanced Research and Invention Agency Bill

Rosie Winterton Excerpts

2nd reading
Tuesday 23rd March 2021 Commons Chamber

[Anthony Browne (South Cambridgeshire) (Con)]

If you do not mind, Mr Deputy Speaker, I wish to make a slight confession: I am suffering from a rather extreme out-of-body experience. I have spent the past three and a half hours listening to Members from all parties—from not just the Conservatives but Labour, the SNP, the Liberal Democrats and the DUP—praising the Advanced Research and Invention Agency. I am having an out-of-body experience not because the House is the most united it has been since I arrived in this place, but because it is so united behind an idea promoted by Dominic Cummings. That shows what an indisputably good idea it must be.

It is absolutely right that the Government do everything they can to promote innovation, which has been the single engine for human progress over the past few centuries. Innovation is the single main reason why our health and wealth are immeasurably better than they were in generations past. Cambridge, my city, is the capital of innovation in the UK and, indeed, in Europe—perhaps in the world. It has had many successes, which have been referred to by a lot of colleagues—it is the global headquarters of AstraZeneca and it has had more Nobel prize winners than almost any country in the world.

One strange feature of innovation is that people often cannot tell where it will lead to when they are doing it. To give one topical example, when the Cambridge researcher Francis Crick was decoding DNA, he had no idea that more than half a century later, it would lead to the Wellcome Sanger Institute in my constituency doing more decoding and genome sequencing of the coronavirus than the rest of the world put together, helping us to track and tackle this pandemic.

The Government do a huge amount to promote innovation already, and we have heard a lot about it this afternoon, so why do we need another agency? Why do we need ARIA? ARIA will help tackle one of the main obstacles of innovation in the public sector, which is that in the public sector, as compared with the private sector, the costs of failure are higher and the rewards for success are lower. What do I mean by that? In the public sector, if somebody fails, they get pilloried in the press and they get the Opposition after them. Ministers have to resign and civil servants lose their job. That does not happen in the private sector. In the public sector, if someone does something that succeeds massively, they do not get bonuses. They are not rewarded by an increase in profits and share prices. The incentives are less.

What we need to do with ARIA is reduce the costs of failure, and that is why it is so important to have a separate, stand-alone organisation that is not part of UKRI—one that has a culture of taking risks and knows that sometimes it is worth having failure. Indeed, if there are not occasional failures, it is not really succeeding in its objective of disrupting and taking risks.

It is important—I urge the Minister to do this—that we help ARIA get more of the rewards for success. Several of my hon. Friends touched on this point earlier. ARIA is able to commercialise and go into business, but let it keep some of the rewards from success, if those projects succeed. That would be a huge incentive for it to try to make sure that those things work.

I have four general points about ARIA. The first is that it must be additional to other forms of research and development. If it is just funding projects that get funded by UKRI already, it is not really doing what it should be. Secondly, it is very important that it can experiment to try out different forms of funding. It has to be able to do a whole range of different types of funding for different projects as it sees fit, and it should be flexible in doing that. For example, we can have a company or academics doing some sort of research that we think is disruptive and amazingly good, but it does not fit into any of the general pots we already have. ARIA needs to be able to give grants to projects that it thinks are worthwhile. It has to have flexibility, and that means not going through the public procurement rules as they exist at the moment.

When I worked in City Hall in London, I was responsible for the London Development Agency, and I did a whole range of projects with public procurement. All I can say is that the only people who think that public procurement rules do not strangle innovation are people who do not have direct experience of them. It is absolutely right that ARIA is exempted from the worst parts of those rules.

Thirdly, picking up on value for money, which some Opposition Members mentioned, it is absolutely right that the Treasury and the Government ensure value for money from public investments across the piece. The Treasury Green Book does that, but it is also right that the Government have a portfolio approach, like a private investor. They might have some lower risk investments in Treasury bonds and then some higher risk investments in venture capital, and they are not all judged by the same rules. We absolutely should not judge ARIA by the same blanket value-for-money rules as we would if we were building a bridge. That would strangle ARIA.

Fourthly, it is absolutely right, as a couple of Members have touched on, that ARIA has multi-annual budgets inasmuch as the Government and the Treasury can allow. Funding disruptive research often takes many years, and simply giving a drip-drip of funding one year at a time will mean a lot of disruptive technologies cannot take flight.

When I was chair of the Government’s Regulatory Policy Committee, I remember civil servants at the Department for Business, Energy and Industrial Strategy saying to me sagely, “Governments have always set up organisations as independent, and then the politicians realise all the problems of independence and then chip away at the independence over coming years, and the organisations gradually get brought down to heel.” It is very important that does not happen to ARIA, otherwise it will lose the reason for its existence. We have heard Opposition Members in particular talk about the need for FOI requests, for procurement rules, for mission statements and value for money assessments. I ask the Minister and the Government not to listen to those siren calls, which will clip ARIA’s wings at birth, and it will then never take flight.

Finally, I just want to settle one little discussion or dispute that we have had this afternoon. Many of my hon. Friends have been making bids for the location of ARIA; we have heard about Bristol, Bolton, Sedgefield, Doncaster and Guildford. I can sort this for the Government. Put the innovation agency where the innovators are: Cambridge—done.

[Madam Deputy Speaker (Dame Rosie Winterton)]

Doncaster.

--- Later in debate ---

[Aaron Bell (Newcastle-under-Lyme) (Con)]

It is a pleasure to follow my hon. Friend the Member for Warrington South (Andy Carter), and a particular pleasure to do so in person. He and I have been hanging around the same Zoom waiting rooms for much of the winter, and it is nice to be back in the Chamber.

As my hon. Friend the Member for Arundel and South Downs (Andrew Griffith) said at the beginning of his speech, today is the national day of reflection as we look back over the past year and remember our collective loss and, for many people, including my hon. Friend, our personal losses, but also look forward to a brighter future. That brighter future is because of science. In the past year, it has been a privilege to serve on the Select Committee on Science and Technology, together with the Chair, my right hon. Friend the Member for Tunbridge Wells (Greg Clark), who spoke earlier, and other Members who have spoken in the debate—my hon. Friends the Members for Bolton North East (Mark Logan) and for Arundel and South Downs, and the hon. Member for Glasgow North West (Carol Monaghan). I praise the Clerks of the Committee for all the work they have done. We have had a number of sessions on covid at very short notice and have also considered ARIA—or ARPA as we knew it at the time, and I have in my hand our report which was published on 12 February.

Looking at the past year and the work that the Science and Technology Committee has done, there is a real read-across from what happened with covid to ARIA. As I said in my intervention on the Secretary of State, at its best ARIA will learn from what we have done on covid in the past year. If covid has a silver lining, it is what it has enabled us to do in the science sphere, allowing us to throw off some of the shackles related to funding, innovation and things such as mRNA vaccines.

The Government have not exactly followed the Committee’s recommendations, and that is fair enough, but the Secretary of State was very forthcoming when he gave evidence to us last week about the reasons for that. As my right hon. Friend the Chair said, it is easy to dissipate £800 million. I know that it sounds like a lot of money, but in the context of our overall science budget it is not quite all that much. The Committee recommended that there be a client, but if there is not to be one, it is important that there is focus. If we are going to have focus, the leadership of ARIA will be key. I hope that our Committee can be involved. There has not been an Order in Council because ARIA does not yet exist, so there is no pre-appointment hearing, but I hope that our Committee can speak with the prospective chair and chief exec of ARIA.

Let me turn to some of the detail. I am pleased to see the range of innovative funding envisaged for ARIA, particularly through prizes, which can leverage huge amounts of private sector investment. We have this target of 2.4% of GDP for R&D. It is all very well spending more Government money, but the key is getting more private sector investment to get us to that 2.4% target. Any ways that we can leverage private sector investment through ARIA would be hugely welcome. We are also looking into grant-prize hybrids, seed grants for very early stage developers and equity stakes. As many hon. Members have said, including my hon. Friend the Member for North East Bedfordshire (Richard Fuller), we need to be better at capturing the commercial benefit of the world-class science that takes place in this country, and perhaps equity stakes through ARIA can be a part of that.

Our Committee took evidence from a number of organisations in our inquiry into what has now become ARIA. We heard from organisations that had worked well, such as DARPA, and some that had not worked quite so well. I wonder whether the sense of crisis to which I referred earlier is necessary for these sorts of things to work. In world war two, the Manhattan project obviously led to the atomic bomb. The cold war led to DARPA and the need for the United States to secure its own defence. What we have seen in the last year with covid has led to so many innovations in vaccines, therapeutics and beyond that will last well beyond this period; as was said earlier, these innovations may ultimately save more lives than have been lost, because of the speed of their development.

If ARIA is to work well, it needs somehow to harness that sense of crisis, and the breakthrough, breakneck response to crisis and existential threat. It needs the space to do so, autonomy from the Government and the freedom to fail. Science often learns more from what does not work than what does.

Before I draw my remarks to a conclusion, it would be remiss of me not to make my own pitch. Keele University in the wonderful constituency of Newcastle-under-Lyme is a fabulous university. It is a university enterprise zone and part of the Energy Research Accelerator, which links up multiple universities and private sector organisations across the west midlands. We also have a fabulous science and innovation park. We are a proud host of Cobra Biologics, one of the manufacturers of the amazing Oxford-AstraZeneca vaccine that is doing so much good in this country. It is not doing so much good elsewhere because of some rather foolish remarks by regulators, but we are very proud of our vaccine; if other countries do not want it, we will have it.

ARIA is a great idea. Like many of its would-be projects, it has the potential to be bold and transformative itself. But it also has the potential to fail, or at least not to work for as long as we might hope. I welcome the 10 years that we have set out in the Bill to give it a chance to work. Many iconoclastic structures end up being captured and overrun by bureaucracy; we must be really careful in that regard. As the Bill progresses through this House and the other place, I hope that the Government will be very firm in resisting all those who would strangle it at birth.

[Madam Deputy Speaker (Dame Rosie Winterton)]

I call the final Back-Bench speaker, Richard Holden.